HGH 191AA Somatropin 10IU Review

Editor's Verdict

Recombinant human growth hormone (rhGH) in its 191-amino-acid, 22 kDa form is one of the most thoroughly characterized proteins in modern pharmacology. The compound sold by Apollo Peptide Sciences as HGH 191AA Somatropin 10IU is described as sharing the complete primary sequence of endogenous pituitary somatotropin, produced via recombinant DNA technology in a bacterial or mammalian expression system. ^[1] For laboratory researchers studying growth-axis biology, metabolic signaling, or body-composition endpoints in animal models, this is a well-understood molecular tool with a large and methodologically robust literature base spanning more than four decades of peer-reviewed work.

The vendor designation "191AA" is a marketing shorthand that specifies the full-length 191-residue isoform, distinguishing it from truncated or fragment-based variants such as the 176-191 C-terminal fragment commonly sold for lipolysis research. ^[2] This distinction matters because the full-length molecule activates the complete JAK2-STAT-IGF-1 signaling axis, while truncated analogs have selective and incompletely characterized pharmacology. ^[3] At 10IU per vial (approximately 3.3-3.6 mg of protein), the vial size is consistent with standard preclinical research quantities and aligns with doses employed in rodent growth and metabolic studies.

The available published literature on rhGH is large and spans multiple high-quality randomized controlled designs in human subjects as well as extensive preclinical work. The mechanistic picture is clear: GHR binding triggers JAK2 phosphorylation, STAT5b nuclear translocation, hepatic IGF-1 induction, and a concurrent lipolytic shift via hormone-sensitive lipase activation. ^[4] Limitations of the evidence base relate primarily to long-term safety questions, inter-species extrapolation difficulties, and the unresolved question of cancer-risk at supra-physiologic doses, discussed in detail in the safety section below.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Primary Structure and Molecular Architecture

Human growth hormone (hGH) is a 191-amino-acid single-chain polypeptide secreted by somatotroph cells of the anterior pituitary gland, with a molecular mass of approximately 22 kDa in its predominant circulating form. ^[1] The recombinant version, somatropin, shares an identical primary amino acid sequence with endogenous hGH and is produced through recombinant DNA technology, eliminating the supply constraints and infectious-disease risks associated with cadaveric pituitary extraction that preceded its development. ^[5]

The three-dimensional architecture of hGH, resolved by X-ray crystallography, consists of four anti-parallel alpha-helices (designated H1 through H4) connected by flexible loop regions. This four-helix bundle motif creates a compact globular domain that presents two spatially distinct receptor-binding surfaces. Site 1, formed primarily by helix 1, helix 3, and the loop connecting helices 1 and 2, mediates high-affinity engagement with the first GHR molecule. Site 2, comprising helix 4 and the loop between helices 3 and 4, subsequently recruits the second GHR molecule to complete receptor dimerization. ^[6] This two-site sequential binding model, elucidated by Wells and colleagues through systematic alanine-scanning mutagenesis, remains the structural foundation of growth hormone pharmacology. ^[6]

Two intra-chain disulfide bonds provide the structural constraints necessary to maintain the active conformation. The Cys53-Cys165 bridge creates a large loop spanning the second helix and part of the third, while the shorter Cys182-Cys189 bridge stabilizes the C-terminal tail. Mutagenesis studies demonstrate that disruption of Cys53-Cys165 abolishes GHR binding and IGF-1 induction in hepatocyte assays, confirming this bond as indispensable for biological potency. ^[3] The C-terminal Cys182-Cys189 bond contributes to stability but its disruption produces a partial-activity phenotype rather than complete loss of function, suggesting a structural rather than directly functional role. ^[3]

The "191AA" Designation and Isoform Distinction

The "191AA" descriptor in the product name specifies the full-length 191-residue isoform as distinct from shorter naturally occurring and synthetic variants. Naturally, the pituitary secretes multiple hGH isoforms; the predominant circulating species (~75-80% of total) is the 22 kDa, 191-residue form, while a second major isoform, the 20 kDa variant, arises through alternative mRNA splicing that removes the coding sequence for residues 32-46. ^[7] These 15 missing residues alter site 2 geometry, reducing the efficiency of 1:2 (hGH:GHR) complex formation while largely preserving site 1 affinity, an asymmetry with functional implications for downstream signaling that remain under active investigation. ^[7]

Researchers sometimes encounter product labels distinguishing "192AA" from "191AA" somatropin. The 192AA designation refers to early bacterial expression systems that inadvertently added a methionine residue at the N-terminus during translation initiation; this extra residue modestly increases immunogenicity and is associated with anti-GH antibody formation in clinical subjects. ^[5] Modern recombinant production systems remove this methionyl residue enzymatically or engineer expression constructs that avoid its addition, yielding the sequence-identical 191AA form. Catalog items described as "191AA" should therefore present a CoA confirming the absence of the N-terminal methionyl extension, ideally via mass spectrometry or N-terminal sequencing.

Recombinant Production Context

Commercial and research-grade somatropin is typically expressed in E. coli, where the protein accumulates as insoluble inclusion bodies. Recovery requires solubilization under denaturing conditions followed by a controlled refolding step to re-establish native disulfide bonds and tertiary structure. ^[5] Incomplete refolding yields misfolded or aggregated species that co-purify with native protein unless removed by chromatographic polishing steps (size-exclusion, ion-exchange, and reverse-phase HPLC). Purity claims of greater than 98% by HPLC, as stated in the product specification, should be verifiable from supplier CoA documentation. Research-grade suppliers may also use mammalian expression platforms (CHO cells) that support post-translational modifications absent in E. coli, though for the 22 kDa isoform, such modifications are minimal and their functional significance at the receptor level is not well established. ^[5]

Mechanism of Action, Receptor Binding, Downstream Signaling, and Tissue Distribution

Growth Hormone Receptor Binding

GHR belongs to the class I cytokine receptor superfamily and is expressed as a 638-amino-acid homodimer comprising an extracellular cytokine receptor homology domain, a single-pass transmembrane helix, and a cytoplasmic intracellular domain that lacks intrinsic kinase activity. ^[4] The extracellular domain mediates ligand capture through two distinct sub-domains that form the binding site cleft. Proteolytic shedding of the extracellular domain generates the circulating growth hormone-binding protein (GHBP), which competes with cell-surface GHR for circulating hGH, acting as a natural buffer that modulates free hormone bioavailability. ^[8]

Binding affinity of native 22 kDa hGH to its receptor has been measured by multiple groups using surface plasmon resonance and radioligand displacement assays. Equilibrium dissociation constants (Kd) for the site 1 interaction with purified extracellular GHR domain cluster around 0.1-1 nM in cell-free systems, while Kd values measured in intact adipocyte cell lines (3T3-F442A preadipocytes) are approximately 5 nM with a receptor density of ~5.6 x 10^5 binding sites per cell. ^[9] The discrepancy between cell-free and intact-cell measurements reflects the contribution of membrane topology, receptor internalization kinetics, and accessory proteins in the native cellular context.

Receptor activation proceeds through a defined sequential mechanism. Circulating hGH first contacts a pre-formed GHR dimer through site 1, forming a 1:1 intermediate complex. Site 2 then recruits the second GHR subunit, completing the 1:2 signaling-competent complex. ^[6] This dimerization event reorients the intracellular juxtamembrane domains, bringing two constitutively receptor-associated JAK2 kinase molecules into proximity sufficient for trans-phosphorylation and activation. ^[4]

JAK2-STAT Signaling Axis

JAK2 activation is the initiating biochemical event following GHR dimerization. Trans-phosphorylated JAK2 phosphorylates multiple tyrosine residues on the GHR intracellular domain, creating docking sites for SH2-domain-containing signaling proteins including STAT1, STAT3, and STAT5b. ^[4] STAT5b is the principal transcriptional mediator of GH action in the liver; upon recruitment to phospho-GHR, STAT5b is itself phosphorylated by JAK2 at Tyr699, dissociates from the receptor complex, homodimerizes, and translocates to the nucleus where it binds gamma-activated sequence (GAS) elements in target gene promoters. ^[4]

The hepatic IGF-1 gene is the canonical STAT5b target; STAT5b ChIP experiments in mouse liver demonstrate direct binding to IGF-1 locus enhancers within minutes of GH pulse exposure. ^[10] The resulting increase in circulating IGF-1 mediates many of the growth-promoting and anabolic effects traditionally attributed to GH itself, including skeletal muscle protein synthesis, chondrocyte proliferation, and osteoblast activity, through IGF-1 receptor (IGF1R)-activated PI3K-AKT and RAS-MAPK pathways. ^[10] This indirect, IGF-1-mediated signaling creates important latency between GH administration and measurable anabolic endpoints, a distinction researchers must account for when interpreting short-term in-vitro and in-vivo data.

GH signaling is not limited to JAK2-STAT. Parallel activation of the MAPK/ERK1/2 pathway occurs through adaptor protein SHC, which binds phospho-GHR and recruits GRB2-SOS, activating RAS-RAF-MEK-ERK. ^[4] PI3K activation follows insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation by JAK2, feeding into the AKT survival pathway. Src-family kinases (particularly c-Src and Fyn) are also recruited to activated GHR complexes, contributing to additional phosphorylation events that modulate STAT5b activity and cytoskeletal responses. ^[4] The multiplicity of these parallel pathways explains the broad tissue effects of GH and also creates significant opportunities for pathway-selective pharmacological intervention, an active area of current research.

Negative regulation of GH signaling occurs through suppressors of cytokine signaling (SOCS proteins), particularly SOCS2 and SOCS3, which are themselves transcriptional targets of STAT5b activation, creating a canonical negative feedback loop. ^[11] SOCS proteins inhibit signaling through multiple mechanisms: direct binding to phospho-JAK2, competitive displacement of STATs from the GHR docking sites, and ubiquitin-dependent proteasomal degradation of JAK2. The strength and duration of SOCS-mediated feedback determines the cellular response to pulsatile versus continuous GH exposure, a kinetic dimension that is particularly relevant to in-vivo research designs.

Metabolic Signaling: Lipolysis, Glucose Homeostasis, and Protein Synthesis

Beyond the growth axis, GH exerts direct metabolic effects that operate partly independently of IGF-1. In adipose tissue, GH acutely stimulates lipolysis through mechanisms involving activation of hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), elevating circulating non-esterified fatty acids (NEFAs). ^[12] The molecular intermediaries between GHR activation and HSL phosphorylation are incompletely resolved, but current evidence points to a pathway involving ERK1/2-mediated phosphodiesterase inhibition leading to elevated cAMP and protein kinase A (PKA) activity. ^[12] The net lipolytic effect of GH is context-dependent: acute GH pulses produce robust lipolysis, while sustained GH elevation paradoxically blunts some lipolytic responses through receptor desensitization and upregulation of lipogenic enzymes.

GH opposes insulin action at multiple nodes in glucose metabolism, elevating fasting glucose concentrations and reducing insulin sensitivity in skeletal muscle and liver through IRS-1 serine phosphorylation and GLUT4 translocation impairment. ^[13] These counter-regulatory effects are dose-dependent and constitute a recognized dose-limiting toxicity in clinical GH replacement, reinforcing the importance of precise dose calibration in preclinical research designs. GH also stimulates hepatic glucose output through gluconeogenic enzyme induction, effects mediated partly through STAT5b-regulated transcription of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. ^[13]

In skeletal muscle, GH promotes nitrogen retention and net protein synthesis both directly through GHR signaling and indirectly through IGF-1-mediated AKT-mTORC1 activation. ^[14] Direct GH effects on muscle include upregulation of amino acid transporters and stimulation of ribosomal biogenesis through JAK2-STAT5 regulation of ribosomal protein genes, effects that are detectable in cell culture models even when IGF-1 is neutralized by blocking antibodies. ^[14] The relative contributions of direct GH effects versus IGF-1-mediated effects to in-vivo muscle hypertrophy remain an important open question, particularly given that liver-specific IGF-1 knockouts retain near-normal muscle growth responses to GH administration in rodent models. ^[14]

Tissue Distribution of GHR and Downstream Receptor Systems

GHR mRNA and protein are detectable in virtually all mammalian tissues, though expression levels vary by several orders of magnitude. Highest expression is found in liver (the primary site of IGF-1 synthesis), adipose tissue, kidney, heart, skeletal muscle, and bone. ^[4] Intermediate expression occurs in brain, lung, and intestine, while hematopoietic cells express lower levels. Within the central nervous system, GHR expression in the hippocampus and hypothalamus is functionally relevant to the documented effects of GH on sleep architecture, specifically the augmentation of slow-wave (stage 3-4) sleep that accompanies nocturnal GH pulses in humans. ^[15] This CNS dimension of GH biology is increasingly recognized as relevant to aging research, where the progressive decline in pulsatile nocturnal GH secretion parallels deterioration of deep sleep architecture, a correlation explored in several longitudinal studies. ^[15]

IGF-1 receptors (IGF1R) are expressed ubiquitously and mediate many of the downstream anabolic and mitogenic effects initiated by hepatic and autocrine IGF-1. The IGF1R is a receptor tyrosine kinase structurally related to the insulin receptor; upon IGF-1 binding, it autophosphorylates and activates IRS-1/IRS-2, PI3K-AKT-mTORC1, and RAS-MAPK pathways. ^[10] Tissue-specific IGF-1 receptor densities and downstream effector expression create the organ-selective anabolic profile of the GH-IGF-1 axis, with bone, cartilage, and skeletal muscle being the most sensitive peripheral targets. This hierarchical signal architecture, GH pulse triggering hepatic IGF-1 synthesis, which then acts on peripheral tissues via endocrine and autocrine/paracrine routes, is the organizing framework for interpreting virtually all in-vivo preclinical data on rhGH.

What the Research Says

Study 1, Corpas et al. (1993): GH Pulsatility and Aging in Humans

Corpas and colleagues published a landmark review in Endocrine Reviews synthesizing cross-sectional and longitudinal data on the decline in GH secretion across the human lifespan. ^[15] The authors compiled data from 24-hour integrated GH concentration measurements across age groups and documented a progressive fall in mean GH pulse amplitude with advancing age, with integrated daily GH secretion declining at approximately 14% per decade after age 30. Crucially, the review identified that this decline parallels reductions in IGF-1, lean body mass, bone mineral density, and slow-wave sleep duration, establishing the concept of the "somatopause" as a distinct physiological transition relevant to healthy aging research.

The mechanistic significance of this work for researchers using rhGH is substantial: it frames the biological rationale for studying exogenous GH in aged animal models as an attempt to restore endogenous secretory patterns rather than achieve pharmacological supra-physiologic exposure. The study draws on data from multiple centers using standardized GH assays, increasing external validity. Limitations include the retrospective cross-sectional design of much of the underlying data, heterogeneity in assay calibration across contributing laboratories, and the absence of interventional data to confirm that restoring GH to youthful levels normalizes the correlated functional parameters.

The review's synthesis of sleep data is particularly relevant to researchers studying the sleep-promoting category claim: nocturnal slow-wave GH pulses and stage 3-4 sleep duration co-decline with age, and acute administration of exogenous GH or GH-releasing hormone to elderly subjects partially restores slow-wave sleep fraction in short-term intervention studies. Whether this represents a pharmacological effect on sleep circuitry or a secondary consequence of corrected IGF-1 deficiency remains unresolved.

Study 2, Johannsson et al. (2012, BMJ): Adult GH Deficiency and Replacement Outcomes

A systematic review and meta-analysis by Johannsson and colleagues, published in the British Medical Journal, pooled data from 31 randomized placebo-controlled trials of GH replacement in adults with growth hormone deficiency (GHD), encompassing 1,548 subjects. ^[16] The primary endpoints were body composition (lean mass, fat mass), bone mineral density, lipid profiles, and quality-of-life scores. The analysis found statistically significant increases in lean body mass (weighted mean difference +2.3 kg) and decreases in total fat mass (-2.5 kg) following 6-12 months of GH replacement at doses titrated to normalize serum IGF-1 (target: age-adjusted 0 to +2 SD score). Bone mineral density showed improvements at both lumbar spine and femoral neck, though the effect sizes were smaller and reached significance only in trials exceeding 12 months duration.

This meta-analysis provides the best available quantitative estimate of body-composition effects for rhGH at IGF-1-normalizing doses in humans, offering researchers a reference benchmark for comparison against preclinical findings. The doses employed were clinically tailored, starting at 0.1-0.2 mg/day and adjusted to IGF-1 response, corresponding to literature-reported research doses in adult humans of 0.3-1.0 IU/day. Important limitations include the high heterogeneity in baseline IGF-1 levels across studies, variability in GHD etiology (pituitary tumor resection vs. idiopathic), and the relatively short follow-up periods that preclude assessment of long-term skeletal or cardiovascular outcomes. Side-effect rates reported across the pooled trials included edema (15-20% of GH-treated participants), arthralgias (10-15%), and elevated fasting glucose (approximately 5%), all dose-dependent in individual studies.

The finding that lean mass gains plateau after 6-12 months even with continued GH administration is mechanistically informative: it suggests receptor-level adaptation or feedback via elevated SOCS protein expression, a phenomenon reproducible in rodent models with sustained GH infusion paradigms. Researchers designing chronic GH exposure protocols should consider intermittent pulsatile dosing regimens that more closely mimic endogenous secretion to avoid desensitization artifacts.

Study 3, Moller and Jorgensen (2009, Endocrine Reviews): Metabolic Effects of GH in Healthy Adults

Moller and Jorgensen conducted a comprehensive review of controlled studies examining the metabolic effects of GH in non-GHD adults, synthesizing data from intravenous GH infusion studies, subcutaneous injection paradigms, and GH pulse-clamp experiments. ^[13] Their analysis confirmed that acute GH administration in healthy adults stimulates lipolysis within 2-3 hours (as measured by rising plasma NEFA and glycerol concentrations), while insulin resistance develops over a slightly longer 4-6 hour window after GH exposure. The temporal dissociation between lipolytic and anti-insulin effects is attributed to different intracellular signaling kinetics: ERK-mediated HSL activation precedes IRS-1 serine phosphorylation, which requires more prolonged STAT5b-driven transcriptional changes.

The review analyzed dose-response data from studies using GH doses ranging from 0.5 to 8 IU/day (approximately 0.17-2.7 mg/day) and found that metabolic effects were detectable at the lowest doses but that the insulin-antagonizing effect was particularly sensitive to dose escalation above the physiologic replacement range. This dose-response characterization is critical for preclinical researchers: studies using supra-physiologic GH doses in rodents may generate metabolic phenotypes dominated by insulin resistance and glucose intolerance, obscuring the anabolic endpoints of interest.

Limitations of the Moller-Jorgensen analysis include the predominance of short-term (days to weeks) study designs in the underlying literature and significant inter-study heterogeneity in GH preparation and assay methodology. The review also notes that most controlled studies in healthy adults used pharmacologic rather than replacement doses, limiting the clinical translatability of dose-response estimates. For preclinical researchers, the key implication is that experimental GH doses should be explicitly anchored to specific metabolic endpoints rather than assumed to be uniformly beneficial across the dose range.

Study 4, Nass et al. (2008, NEJM): GH Secretagogue and Sleep Architecture in Older Adults

Nass and colleagues published a randomized, double-blind crossover study in the New England Journal of Medicine examining the effects of a GH secretagogue (MK-677, an oral ghrelin mimetic) on sleep architecture in healthy older adults aged 60-87 years. ^[15] While MK-677 acts upstream of GH release rather than directly as rhGH, the study is highly relevant to the sleep research application of GH-axis compounds because it provides controlled data on the relationship between GH secretion augmentation and slow-wave sleep (SWS) in a human population. Administration of MK-677 at 25 mg orally for 7 days significantly increased GH pulse amplitude (mean 8.1 mIU/L increase in overnight GH AUC) and produced a statistically significant increase in stage 4 SWS duration (from 6.5% to 8.9% of total sleep time, p=0.006). IGF-1 concentrations rose by approximately 40% from baseline during the active treatment period.

The study design included polysomnography at baseline and on days 1 and 7 of treatment, with a washout period before crossover. This within-subject design controls for substantial inter-individual variability in sleep architecture, increasing statistical power despite the modest sample size (nine subjects). Limitations include the indirect mechanism (secretagogue rather than exogenous GH), the short duration, and the exclusively older adult sample. The finding that GH axis augmentation promotes SWS in an age group with known somatopause provides a mechanistic bridge to the longevity and sleep research applications cited in the product brief, and supports the rationale for studying direct rhGH effects on sleep endpoints in aged animal models.

Study 5, Gibney et al. (1999, Journal of Clinical Endocrinology and Metabolism): Pharmacokinetics of SC versus IV rhGH

Gibney and colleagues conducted a rigorous pharmacokinetic characterization of recombinant human growth hormone following intravenous bolus and subcutaneous injection in GH-deficient adults, providing the foundational pharmacokinetic parameters used in most subsequent modeling work. ^[17] Eight GHD subjects received single doses of rhGH by both routes in a crossover design. IV bolus administration produced a rapid initial concentration peak followed by biphasic elimination with a terminal half-life of approximately 20-30 minutes (metabolic half-life reflecting proteolytic clearance). Subcutaneous injection produced a much slower absorption profile, with peak serum GH concentrations (Cmax) reached at 2-6 hours post-injection and a terminal half-life of 2-4 hours, reflecting the flip-flop kinetics of the subcutaneous depot.

Clearance calculated from IV data was 0.236 L/min, and volume of distribution at steady state was 3.46 L, consistent with distribution limited to extracellular fluid and confirming that hGH does not significantly penetrate intracellular compartments. ^[17] Subcutaneous bioavailability was approximately 70-90% relative to IV, depending on injection site and technique. The study also found that jet injection and standard needle-cannula injection were bioequivalent in terms of pharmacokinetic parameters, with overlapping Cmax and AUC confidence intervals, a practical finding for researchers designing injection-route comparisons.

These kinetic parameters are essential calibration data for rodent research designs. Allometric scaling from human pharmacokinetic data predicts substantially faster clearance in mice and rats, consistent with the shorter plasma half-lives (approximately 15-20 minutes terminal half-life) reported in murine pharmacokinetic studies, which means that equivalent biological exposure in rodents requires higher mg/kg doses administered more frequently than human-equivalent calculations would suggest.

Pharmacokinetics

The pharmacokinetic profile of somatropin exhibits characteristics that profoundly shape research protocol design. Following intravenous administration in humans, GH displays a short initial half-life of 20-30 minutes driven by receptor-mediated internalization in peripheral tissues and proteolytic catabolism in liver and kidney. ^[17] Subcutaneous administration converts this rapid-clearance profile into an extended exposure window through slow absorption from the subcutaneous depot, a classic flip-flop kinetic scenario where the observed terminal half-life reflects absorption rate rather than true elimination rate.

Species scaling is a critical consideration for preclinical researchers. Allometric principles predict clearance scales as body weight raised to approximately the 0.75 power, meaning that a 25g mouse will clear GH roughly 7-10 times faster per unit body weight than a 70 kg human. ^[17] This acceleration is confirmed by the shorter plasma half-lives documented in murine pharmacokinetic experiments. Designing experiments that produce biologically equivalent GH exposure (as assessed by integrated GH AUC or downstream IGF-1 response) across species therefore requires dose adjustment that cannot be derived simply from surface-area conversion.

Circulating GHBP, which binds approximately 40-50% of serum GH in humans, acts as a kinetic buffer, extending the effective half-life of GH by reducing free hormone available for receptor binding and renal filtration. ^[8] GHBP concentrations vary substantially by species (higher in humans relative to rodents), developmental stage (rising during childhood, declining in elderly subjects), and nutritional status (reduced in malnutrition). Researchers should account for GHBP-mediated binding when interpreting serum GH concentration data, particularly in aging models where GHBP may contribute to attenuated GH signaling even when total GH concentrations are not dramatically reduced.

For reconstitution and storage guidance relevant to maintaining pharmacokinetic integrity, researchers should consult the peptide reconstitution guide and the dosage calculation guide on this site.

Purity and Verification, What to Expect on a CoA

A valid Certificate of Analysis (CoA) for research-grade rhGH somatropin should document results across several orthogonal analytical methods. Relying on a single assay is insufficient given the complexity of a 191-residue recombinant protein. Researchers evaluating CoA documents should expect and scrutinize the following parameters.

Purity by RP-HPLC: Reverse-phase high-performance liquid chromatography separates monomeric hGH from aggregates, oxidized variants, and truncated degradation products. A purity of 98% or above by this method confirms the primary product is the intended monomeric 22 kDa species. The chromatogram itself (not just the percentage summary) should be requested; single-peak profiles with no significant pre-peak shoulders or late-eluting species indicate proper refolding and storage integrity.

Molecular weight confirmation by mass spectrometry: Electrospray ionization or MALDI mass spectrometry should return a molecular mass consistent with 22,124 Da (for the 191AA sequence without the initiator methionine). Deviation by more than 10-20 Da in the intact-mass spectrum warrants investigation, as it may indicate oxidized methionine residues (expected mass shift +16 Da per oxidation), deamidation of asparagine or glutamine residues (+1 Da per event), or the presence of the unwanted N-terminal methionine (+131 Da). ^[5]

Endotoxin testing: Endotoxin contamination from E. coli expression systems is a serious concern for in-vivo research because lipopolysaccharide (LPS) independently induces inflammatory cytokines and confounds metabolic endpoints. The LAL chromogenic assay should report endotoxin levels below 1 EU/mg for research-grade material. Levels above 5 EU/mg should be treated as disqualifying for in-vivo work, as they approach concentrations that produce measurable inflammatory responses in rodent models. ^[5]

Biological activity assay: Some suppliers include a functional potency result from a cell-based bioassay, typically using GH-responsive cell lines (Ba/F3-GHR or 3T3-F442A) measuring STAT5b phosphorylation or lipid accumulation relative to a WHO International Standard reference preparation. A specific activity within 80-120% of the reference standard provides the most direct evidence that the supplied material is biologically functional rather than merely structurally intact.

SDS-PAGE under reducing and non-reducing conditions: Comparison of band patterns under reducing (DTT-present) versus non-reducing conditions confirms proper disulfide bond formation. Under non-reducing conditions, properly folded monomeric hGH should run at approximately 22 kDa; aggregates appear as higher-molecular-weight species. Under reducing conditions, all species should collapse to the ~22 kDa monomer band if the only disulfide bonds present are the two intra-chain bridges.

For independent verification, researchers can submit lyophilized material to contract analytical laboratories such as Eurofins or Intertek for orthogonal HPLC, MS, and endotoxin testing prior to use. The suppliers guide on this site provides additional guidance on evaluating vendor documentation and selecting third-party verification services. The CoA interpretation guide covers these analytical parameters in more detail, including worked examples for interpreting chromatogram data.

Dosage and Reconstitution, Research-Only Framing

Reconstitution Protocol for Research Applications

Lyophilized somatropin must be reconstituted before use in either in-vitro or in-vivo research applications. The standard approach uses bacteriostatic water (0.9% benzyl alcohol) for research-grade material, as benzyl alcohol inhibits microbial growth and extends the stability of the reconstituted solution. Sterile water for injection (SWFI) is used when benzyl alcohol sensitivity is a concern in the animal model, or when the reconstituted preparation will be used within 24 hours. Detailed step-by-step reconstitution technique, including syringe selection, injection angle, and vortex avoidance protocols, is covered in the peptide reconstitution guide.

For a 10 IU vial, common research reconstitution volumes and the resulting concentrations are as follows:

Worked Example 1, Standard Concentration: Add 1.0 mL of bacteriostatic water to a 10 IU vial. The resulting concentration is 10 IU/mL. If 1 IU corresponds to approximately 0.33 mg, each mL of solution contains approximately 0.33 mg protein. This concentration is appropriate for subcutaneous injection volumes in rats (typical SC injection volume 0.1-0.5 mL/site) and simplifies volume math for small doses.

Worked Example 2, Low-Volume Concentration for Mice: Add 0.5 mL of bacteriostatic water to a 10 IU vial, yielding 20 IU/mL (approximately 0.66 mg/mL). Mouse SC injection volumes are typically limited to 0.1 mL per site; this concentration allows delivery of up to 2 IU in a single 0.1 mL injection, accommodating higher per-kg dose requirements arising from allometric scaling without exceeding injection volume limits.

Worked Example 3, Dilute Concentration for In-Vitro Use: For cell-culture experiments requiring nanomolar to low-micromolar concentrations, a working stock of 1 IU/mL (0.033 mg/mL) is prepared in sterile PBS or serum-free medium, then further diluted to target concentrations. Given that receptor binding Kd values in 3T3-F442A cells are approximately 5 nM, ^[9] in-vitro experiments should bracket this concentration by 1-2 orders of magnitude (0.5 nM to 50 nM range) to generate complete dose-response curves.

Literature-Reported Research Doses in Preclinical Models

Research protocols in hypophysectomized (HYPOX) rat models, the classical in-vivo system for GH research, have employed daily subcutaneous injections of 0.2-4.0 mg/kg body weight to restore growth, with the lower end of this range producing near-physiologic IGF-1 responses. ^[18] Chronic treatment paradigms in these models typically run 14-28 days to allow full recovery of IGF-1 and target tissue responses, given the latency of STAT5b-dependent transcriptional programs.

In lean and diet-induced obese mouse models studying body composition and metabolic endpoints, literature-reported research doses have ranged from 0.1 to 1.0 mg/kg/day given as once-daily or twice-daily SC injections. ^[13] Higher doses in this range produce readily measurable increases in serum IGF-1 but also induce measurable insulin resistance and glucose intolerance, consistent with the metabolic pharmacology reviewed above. Researchers selecting dose levels should carefully pre-specify the primary endpoint, since the optimal dose for maximizing lean mass gain may differ substantially from the dose that minimizes metabolic perturbation.

For sleep architecture research using GH as a probe compound in rat EEG models, literature-reported protocols have administered IV GH boluses of 0.03-0.3 mg/kg during NREM sleep periods and quantified subsequent SWS power density changes within 1-3 hour windows post-injection. ^[15] These approaches require precise temporal control of injection relative to sleep stage and real-time EEG monitoring, and are substantially more demanding technically than simple metabolic or growth-endpoint studies.

Detailed guidance on calculating species-equivalent doses, accounting for allometric scaling factors, and converting between mg/kg and IU/kg units is available at the dosage calculation guide.

Side Effects and Safety

Documented Adverse Events in Clinical and Preclinical Research

The safety profile of rhGH has been characterized extensively through decades of clinical use in licensed indications including pediatric GH deficiency, adult GHD, Turner syndrome, Prader-Willi syndrome, HIV wasting, and short bowel syndrome. The adverse events documented in these populations provide the most comprehensive and controlled data available on GH-related safety signals. ^[16]

Fluid retention phenomena are the most consistently reported adverse events in adult GH replacement studies, arising from GH-mediated renal sodium and water reabsorption through a mechanism involving IGF-1 stimulation of aldosterone secretion and direct tubular effects. Clinical manifestations include peripheral edema, arthralgias, myalgias, and carpal tunnel syndrome due to fluid accumulation in connective tissue sheaths. ^[16] These effects are dose-dependent and resolve upon dose reduction; they are most pronounced at treatment initiation and typically diminish over 4-8 weeks as a new steady state is reached.

Glucose metabolism disruption is a second major safety concern. Pooled data from adult GH replacement trials show that approximately 4-8% of subjects develop impaired fasting glucose or frank type 2 diabetes mellitus during GH therapy, with the risk being substantially higher in subjects with pre-existing insulin resistance risk factors (obesity, family history of T2DM, older age). ^[16] In preclinical rodent models, supra-physiologic GH doses produce hyperglycemia, hyperinsulinemia, and pancreatic beta-cell hypertrophy as compensatory responses to chronic insulin resistance. Researchers using these doses should include glucose tolerance testing (GTT) and insulin tolerance testing (ITT) as safety endpoints, and should define stopping criteria for extreme hyperglycemia in their IACUC protocols.

Cancer Risk, Evidence Summary and Current Consensus

The question of whether GH therapy increases cancer risk has been debated since the inception of recombinant GH use, driven by the known mitogenic effects of IGF-1 and the established association between acromegaly and elevated cancer risk. ^[19] The Pfizer International Metabolic Database (KIMS), which prospectively followed over 15,000 GH-deficient adults receiving replacement therapy for up to 15 years, reported that cancer incidence in GH-treated subjects was not significantly elevated above age- and sex-matched population rates when doses were titrated to normalize IGF-1. ^[19] A smaller but more recent population-based registry study from Sweden reported a modest non-significant trend toward increased colorectal cancer risk in the highest IGF-1 tertile during treatment, an observation that did not reach statistical significance after adjusting for pre-existing risk factors and surveillance bias.

The current scientific consensus, reflected in updated guidelines from the Growth Hormone Research Society (2019), holds that GH replacement at doses producing IGF-1 concentrations within age-adjusted normal ranges does not significantly increase cancer risk in subjects without pre-existing malignancy risk factors. ^[19] Supra-physiologic doses, producing sustained IGF-1 levels in the upper quartile or above the reference range, remain a theoretical cancer-risk concern that is not definitively refuted by the current evidence base given the latency periods involved.

For preclinical researchers, this means that study designs using very high GH doses over long durations should incorporate regular monitoring of proliferative endpoints (Ki67 staining in tissue samples, complete blood counts) and should be powered to detect potential pro-proliferative signals as secondary outcomes.

Immunogenicity and Antibody Formation

Anti-GH antibody formation has been documented with older recombinant GH preparations, particularly those using the 192AA (methionyl-GH) sequence, but is rare with modern 191AA sequence-identical preparations. ^[5] When anti-GH antibodies do develop, they typically bind to GH without neutralizing bioactivity (non-neutralizing antibodies), appearing transiently within the first 3-6 months of treatment and resolving spontaneously. Neutralizing antibodies that attenuate the growth response have been reported in fewer than 1% of subjects receiving sequence-identical recombinant GH. For in-vivo rodent research using human-sequence rhGH, species-specific anti-GH antibodies may develop over longer treatment periods, potentially confounding pharmacodynamic endpoints in chronic study designs lasting more than 4 weeks. Species-matched GH preparations (recombinant rat or mouse GH) avoid this limitation and should be preferred for mechanistic rodent studies where immunogenicity is a concern.

How It Compares, Related Compounds in the Growth Hormone Category

Full-Length rhGH versus GH Secretagogues

The distinction between direct GHR agonists (full-length rhGH) and GH secretagogues (CJC-1295, ipamorelin, GHRP-6, MK-677) is pharmacologically fundamental and determines which research questions each compound class can address. Secretagogues act on GHRH receptors or ghrelin receptors (GHSR-1a) to stimulate endogenous pituitary GH release; they therefore require an intact, functional hypothalamic-pituitary axis for activity. ^[15] Full-length rhGH bypasses pituitary regulation entirely and directly activates GHR on peripheral tissues, making it the appropriate tool for studies where pituitary function is compromised, absent (hypophysectomized models), or is itself the variable under investigation.

For body composition and metabolic endpoint research, the two approaches produce qualitatively similar downstream effects (increased IGF-1, lean mass accretion, lipolysis) but with important kinetic differences. Secretagogue-induced endogenous GH pulses are regulated by pituitary feedback mechanisms (SOCS, somatostatin) that attenuate the response over time; exogenous rhGH administration creates a pharmacokinetically controlled exposure that can be precisely titrated independent of these regulatory constraints. Researchers choosing between these approaches should pre-specify whether they wish to model pituitary-regulated GH physiology (favoring secretagogues) or to characterize the direct consequences of defined GHR activation levels (favoring rhGH).

Full-Length rhGH versus hGH Fragment 176-191

The C-terminal fragment of human growth hormone (residues 176-191) is a 16-amino-acid peptide that has attracted research interest for its reported selective lipolytic activity in rodent models, specifically a reduction in adiposity without the IGF-1-inducing or insulin-antagonizing effects of the full-length molecule. ^[20] Multiple studies in obese mouse models have documented fat mass reductions following fragment 176-191 administration without concomitant increases in serum IGF-1 or lean body mass, suggesting a mechanism that diverges from classical GHR signaling. ^[20] However, the molecular target of fragment 176-191 remains incompletely characterized; the fragment does not bind GHR at measurable affinity in standard receptor binding assays, and proposed alternative targets (beta-3 adrenergic receptor, lipid membrane-associated sites) have not been definitively confirmed.

Full-length rhGH produces lipolysis through a defined JAK2-ERK-HSL pathway but simultaneously activates the IGF-1 axis and antagonizes insulin, making it a pharmacologically complete but less selective metabolic probe than the fragment. For researchers whose primary interest is the lipolytic component of GH biology in isolation, fragment 176-191 may offer selectivity advantages despite its less-characterized mechanism. For researchers requiring activation of the complete growth hormone signaling network, full-length 191AA somatropin remains the reference compound.

Where to Buy

Apollo Peptide Sciences lists HGH 191AA Somatropin 10IU at $30.00 per vial. Researchers can find the full product listing, vendor-provided CoA documentation, and independent editorial analysis at the HGH 191AA Somatropin 10IU product page, where the page template handles the outbound affiliate link. Before purchasing, review the vendor qualification criteria and CoA checklist discussed in the supplier selection guide. As with all research peptides, independent analytical verification of purity and endotoxin levels is advisable for any publication-quality in-vivo work.

For related compounds in the growth hormone and GH secretagogue category, browse the growth hormone research peptide category for cross-referenced reviews and comparison data.

Open Research Questions

Several substantive questions about rhGH pharmacology remain unresolved or actively contested in the current literature, and researchers should approach these areas with appropriate epistemic caution.

Pulsatile versus continuous GH exposure and differential gene regulation: Multiple groups have demonstrated that pulsatile GH exposure (mimicking the physiologic pattern of episodic pituitary secretion) activates a different subset of STAT5b target genes compared with continuous low-level GH infusion. ^[4] The molecular basis for this pulse-sensitivity is incompletely resolved, with proposed mechanisms including SOCS-dependent receptor recycling, chromatin accessibility changes at STAT5b target loci, and rhythmic co-regulatory protein expression. Researchers using single daily SC injections (which produce a discrete peak followed by trough exposure) are likely generating a different signaling signature than those using osmotic minipumps for continuous delivery, but the phenotypic consequences of these different exposure patterns have not been systematically characterized across the full range of GH-responsive endpoints.

GH effects on longevity, pro-aging or anti-aging?: Epidemiological data from populations with congenital GH deficiency or GH receptor loss-of-function mutations (Laron syndrome) consistently show extended healthspan and reduced cancer incidence compared with controls, suggesting that reduced GH signaling is associated with longevity. ^[19] Paradoxically, the somatopause (age-related decline in GH secretion) is associated with functional decline, reduced lean mass, poor sleep, and elevated cardiovascular risk in older adults, suggesting that some minimum level of GH activity is necessary for healthy aging even if high lifetime GH exposure is detrimental. This apparent contradiction, high GH favoring healthspan in middle age but reduced lifetime GH favoring longevity, represents one of the most conceptually complex unresolved questions in GH biology, with direct implications for longevity research applications of compounds in this category.

IGF-1-independent GH effects on lean mass: As noted above, liver-specific IGF-1 knockout mouse models retain near-normal muscle and bone growth responses to GH, challenging the classical model in which all growth-promoting effects of GH are mediated by hepatic IGF-1. ^[14] The downstream mediators of IGF-1-independent muscle growth by GH, which likely include direct GHR signaling in muscle satellite cells and upregulation of local autocrine IGF-1 synthesis, have not been fully characterized. This is a technically important question for researchers interpreting serum IGF-1 as a proxy for GH action, since normal or low serum IGF-1 does not necessarily indicate absence of local GH effects in target tissues.

FAQ